<![CDATA[Background: Hepatitis C (HCV) infection is the most commonly acquired infection for patients on hemodialysis and is associated with significant morbidity and disease progression. The efficacy and the safety of direct-acting antivirals (DAA) in patients with HCV in Yemen are still under investigation. Objective: To evaluate the effectiveness and safety of Sofosbuvir and Daclatasvir in the treatment of HCV infection among Yemeni patients who are on hemodialysis. Method: Prospective study of twenty-eight Yemeni patients confirmed with HCV infection who were undergoing hemodialysis during the period from the beginning of January 2023 to the end of December 2024. This study was conducted in the dialysis department at Al Gomhori Hospital in Taiz City, Yemen.Results: During the study period, a Total of 28 Yemeni patients were included: 14 (50%) males and 14 (50%) females, aged 18 to 70 years, with a mean age of 44 ± 12 years. The viral load at the beginning of the study was low in most patients (21, 75%), moderate in 1 (4%), and high in 6 (21%). Early virological response ( EVR) was achieved in 25 (89.03%) patients. One patient(3,6%) had detectable target post treatment, one patient (3,6%) died during the study period, and one patient (3,6%) experienced a side effect that led to discontinuation of the drugs. After 12 weeks of stopping the drugs, sustained virological response (SVR) was achieved in 25 (100%) patients. Conclusion: The combination of Sofosbuvir and daclatasvir was effective and safe in treating HCV infection among Yemeni patients undergoing hemodialysis]]>
